Asthma Management — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for asthma management. 252 active patents protecting 6 drugs from 6+ originators. First major cliff: 2027. Daily refresh.

6
Approved drugs
252
Active US patents
65/100
Avg vulnerability
$5.7B
Annual revenue covered

Originators in Asthma Management

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Pfizer Inc. 70 patents AstraZeneca K.K. 37 patents Merck & Co. 22 patents Covis 4 patents Padagis Us 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating asthma management. Each bar = one year. Y-axis scaled to peak year (56 patents).

12
26
5
27
12
28
9
29
8
30
36
31
1
32
24
34
22
35
14
36
6
37
7
38
56
39
28
40
7
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Epipen
epinephrine
 Pfizer Inc. 70 61 — 2026-12-12
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Omnaris
CICLESONIDE
 Covis 4 80 — 2028-02-01
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8975243 Pulmicort Respules method of use 93 2026-11-09
9119863 Pulmicort Respules method of use 93 2026-11-09
8497258 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
8460641 Verdeso method of use 80 2027-08-13

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
10406332 Elocon formulation 25 2034-03-13
8763222 Elocon formulation 31 2032-02-08
11679210 Elocon formulation 33 2038-09-03
9937189 Elocon formulation 33 2034-09-04
10376526 Elocon formulation 33 2034-09-04
10561672 Elocon formulation 33 2034-09-04
9370483 Elocon formulation 33 2034-09-04
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06

Related